On January 16, 2024 Carcell Biopharma ("Carcell") and CATUG Biotechnology ("CATUG") reported their collaboration to provide lipid nanoparticle (LNP) services worldwide (Press release, Carcell Biopharma, JAN 16, 2024, View Source [SID1234639240]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This partnership aims to deliver contract research and manufacturing services globally for clients developing LNP-based drugs. These services will utilize Carcell’s proprietary cationic lipids and unique high throughput in vivo lipid screening platform, coupled with CATUG’s advanced capabilities for large-scale manufacturing of LNP-based drugs. Under the terms of the agreement, CATUG will have non-exclusive rights to utilize Carcell’s LNP technology for servicing its clients.
Lanlin Wu, CEO of Carcell, shared Carcell’s privilege to have CATUG as a strategic partner. She commended CATUG as the embodiment of the high execution speed of Chinese companies and is emerging as an industrial benchmark for gene therapy and nucleic acid drug production. Leveraging a proprietary large lipid library and internally-developed high-throughput formulation technology, Carcell has identified lipids with global intellectual property rights. When compared to industry benchmarks, these novel LNPs have demonstrated superior potency in applications that include vaccines and gene editing. Ms Wu believes that the partnership with CATUG unlocks multiple opportunities in the global non-viral nucleic acid delivery space and will contribute to the dynamic growth of the cell and gene therapy field.
Dr. Xiao Wang, CEO of CATUG, expressed that CATUG is honored to be in a strategic partnership with Carcell, whom possesses a world-class LNP development team and technical capabilities. As CATUG is committed to providing a one-stop CRDMO (Contract Research, Development and Manufacturing Organization) solution to customers globally, she believes that this newly formed strategic partnership with Carcell will empower customers who are seeking unique and high quality LNPs for drug delivery, for instance extra-hepatic delivery to immune cells. Such a partnership presents many opportunities for both parties and greatly accelerates R&D of various gene therapies and nucleic acid drugs.